Business Context and Reporting Period
Company: Graham Corporation (GHM)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended June 30, 2025 (First Quarter of Fiscal Year 2026)
Business Overview: A global leader in designing and manufacturing mission-critical fluid, power, heat transfer, and vacuum technologies for the Defense, Energy & Process, and Space industries. The company operates through wholly-owned subsidiaries including Barber-Nichols and P3 Technologies.
Key Financial Metrics
| Metric | Q1 FY2026 (Jun 30, 2025) | Q1 FY2025 (Jun 30, 2024) |
|---|---|---|
| Net Sales | $55,487 | $49,951 |
| Gross Profit | $14,721 | $12,368 |
| Gross Margin | 26.5% | 24.8% |
| Operating Income | $4,964 | $3,224 |
| Net Income | $4,595 | $2,966 |
| Diluted EPS | $0.42 | $0.27 |
| Adjusted EBITDA | $6,838 | $5,137 |
| Cash and Equivalents | $10,753 | $21,611 |
| Operating Cash Flow | ($2,259) | $8,716 |
| Capital Expenditures | $7,004 | $2,978 |
| Backlog | $482,860 | $396,775 |
Note: All dollar amounts in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% year-over-year, driven primarily by a 33% surge in Energy & Process sales (due to Chemical/Petrochemical and New Energy markets) and strong aftermarket sales.
- Profitability: Gross margin expanded 170 basis points to 26.5%, attributed to fixed overhead leverage, improved sales mix, and better defense contract execution.
- Cash Flow: Operating cash flow turned negative ($2.3M outflow) compared to a positive $8.7M in the prior year. This was primarily due to the payment of fiscal 2025 bonuses (including a $4.3M performance bonus) and increased capital expenditures.
- Orders and Backlog: Orders booked were $125.9M, a 126% increase year-over-year, resulting in a book-to-bill ratio of 2.3x. Total backlog grew 22% to $482.9M, with Defense representing 87% of the total.
- Capital Spending: Capital expenditures more than doubled to $7.0M, focused on a new manufacturing facility in Batavia, NY, and a cryogenic testing facility in Florida.
Guidance, Outlook, and Risks
Full Year Fiscal 2026 Guidance
- Net Sales: $225,000 - $235,000
- Gross Profit Margin: 24.5% - 25.5% (includes estimated tariff impact of $2M-$5M)
- SG&A Expenses: 17.5% - 18.5% of sales
- Effective Tax Rate: 20% - 22%
- Adjusted EBITDA: $22,000 - $28,000
- Capital Expenditures: $15,000 - $18,000
Management Commentary
Management highlighted strong demand in the Defense sector, including a recent $25.5M follow-on order for the MK48 Mod 7 Heavyweight Torpedo. The Energy & Process sector is seeing growth in hydrogen and small modular nuclear reactor (SMR) markets. Leadership changes occurred in June 2025, with Matthew J. Malone assuming the CEO role.
Risks and Contingencies
- Tariffs: Estimated potential impact of increased tariffs for the full year is between $2M and $5M.
- Legal: Ongoing asbestos-related lawsuits (management does not expect a material adverse effect) and a concluded investigation into misconduct at the India subsidiary (GIPL), which resulted in employee terminations and regulatory reporting.
- Market Volatility: Exposure to foreign currency fluctuations and geopolitical tensions affecting supply chains and raw material costs.
Investor Verification Checklist
- Backlog Conversion: Verify the timeline for revenue recognition of the $482.9M backlog, noting that 35-40% is expected within one year and the majority of long-term orders are Defense-related.
- Cash Flow Sustainability: Monitor operating cash flow recovery in subsequent quarters following the large bonus payments and capital expenditure outlays in Q1.
- Tariff Impact: Track the actual realization of the estimated $2M-$5M tariff cost impact on gross margins throughout the fiscal year.
- Capital Project Completion: Confirm the on-time completion and funding of the new Batavia manufacturing facility and Florida cryogenic testing facility.
- Legal Resolution: Review updates on the GIPL investigation and asbestos litigation to ensure no material financial impact materializes.